Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).

NCT02318667 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

BIOLOGICAL: Golimumab

Sponsor

Merck Sharp & Dohme LLC